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Autonomic nervous system involvement in
pulmonary arterial hypertension
Mylène Vaillancourt†, Pamela Chia†, Shervin Sarji, Jason Nguyen, Nir Hoftman, Gregoire Ruffenach,
Mansoureh Eghbali, Aman Mahajan and Soban Umar*
Abstract: Pulmonary arterial hypertension (PAH) is a chronic pulmonary vascular disease characterized by increased
pulmonary vascular resistance (PVR) leading to right ventricular (RV) failure. Autonomic nervous system involvement
in the pathogenesis of PAH has been demonstrated several years ago, however the extent of this involvement is not
fully understood. PAH is associated with increased sympathetic nervous system (SNS) activation, decreased heart rate
variability, and presence of cardiac arrhythmias. There is also evidence for increased renin-angiotensin-aldosterone
system (RAAS) activation in PAH patients associated with clinical worsening. Reduction of neurohormonal activation
could be an effective therapeutic strategy for PAH. Although therapies targeting adrenergic receptors or RAAS
signaling pathways have been shown to reverse cardiac remodeling and improve outcomes in experimental
pulmonary hypertension (PH)-models, the effectiveness and safety of such treatments in clinical settings have
been uncertain. Recently, novel direct methods such as cervical ganglion block, pulmonary artery denervation
(PADN), and renal denervation have been employed to attenuate SNS activation in PAH. In this review, we
intend to summarize the multiple aspects of autonomic nervous system involvement in PAH and overview
the different pharmacological and invasive strategies used to target autonomic nervous system for the
treatment of PAH.
Keywords: Pulmonary arterial hypertension, Autonomic nervous system, Right ventricle, Sympathetic nervous
system, Renin angiotensin aldosterone system
Overview of the autonomic regulation of heart
and lungs
The autonomic nervous system
The autonomic nervous system is composed of sympa-
thetic and parasympathetic divisions and is often divided
by neural and endocrine regulatory components. The
sympathetic nervous system (SNS) originates from the
thoracolumbar region of the spinal cord (Fig. 1). Short
preganglionic fibers from the T1-L2 segments synapse on
paravertebral or prevertebral ganglia, enabling long post-
ganglionic fibers to innervate target organs such as the
heart and lungs. On the other hand, the parasympathetic
nervous system originates from cranial nerves III, VII, IX,
and X and the sacral nerves S2-S4. In general, parasympa-
thetics cause vasodilation of blood vessels including the
pulmonary vasculature, and sympathetics cause vasocon-
striction [1] (Table 1).
Autonomic innervation of the pulmonary vasculature
The pulmonary vasculature is innervated by sympathetic,
parasympathetic, and sensory nerve fibers. Increased vas-
cular resistance is mediated by α-adrenoreceptors upon
sympathetic nerve stimulation [2]. Noradrenergic fibers
are activated by baroreceptors in the pulmonary artery [3]
and proximal airway segments [4]. Chemoreceptors re-
spond to decreased arterial PO2 levels to increase sympa-
thetic nerve stimulation by the sympathetic chain neurons
[2, 5]. Parasympathetic activation via vagal stimulation re-
sults in cholinergic-mediated relaxation of pulmonary ar-
teries [6]. Many other factors (i.e. non-adrenergic and
non-cholinergic mediators, peptides, trophic factors, dif-
ferential release of transmitters by high or low frequencies)
are implicated in sympathetic and parasympathetic regula-
tion of lung vasculature, though their functions have not
entirely been elucidated [7] (Table 1).
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Autonomic innervation of the heart
The heart is also innervated by both parasympathetic and
sympathetic fibers (Fig. 1). The parasympathetic fibers are
responsible for decreasing chronotropy, dromotropy, and
inotropy via cholinergic action on cardiac M2 receptors.
The SNS acts on β1 adrenergic receptors to increase
chronotropy, dromotropy, and inotropy of the heart [8].
Interestingly, β-adrenergic stimulation has been shown to
have a significantly greater positive inotropic effect on left
ventricular (LV) contractility than on right ventricular
(RV) contractility [9]. On the contrary, adrenergic stimula-
tion of alpha 1 receptors result in increased inotropy in
the LV but decreased inotropy in the RV [10] (Table 1).
Patients with PAH often have normal systemic blood
pressures and lung volumes. However, they may suffer
from hypoxia, hypercarbia, acidosis, and, in later stages,
RV hypertrophy and failure. Neural pathways controlling
the heart and lungs are described in detail within current
scientific literature [11].
Autonomic nervous system and RAAS involvement in
PAH
PAH is a clinical syndrome characterized by pathologic
pulmonary 1) vasoconstriction, 2) vascular remodelling,
and 3) thrombosis. Progressive sequelae include in-
creased pulmonary vascular resistance (PVR), RV hyper-
trophy and dysfunction, and ultimately death. The
extent of involvement of the autonomic nervous system
in the pathogenesis of PAH is not fully understood. It is
postulated that the patients with PAH often have a low
Fig. 1 Schematic diagram summarizing autonomic nervous system involvement in PAH and various therapeutic strategies targetting the activation of SNS
and RAAS in PAH. PAH is associated with increased sympathetic nervous system (SNS) and renin-angiotensin-aldosterone-system (RAAS) activation. The
central nervous system provides autonomic output to the lungs and heart mainly through cranial nerves IX and X. The parasympathetic nervous system
(shown in blue) originates from cranial nerves III, VII, IX, and X and the sacral nerves S2-S4. The SNS (shown in red) originates from the thoracolumbar
region of the spinal cord and modulates; i) vascular and airway reactivity in the lungs, ii) heart rate and contractility in the heart and iii) RAAS activation in
the kidneys and adrenal glands. Consequently, RAAS activation generates vasoactive compounds that result in pulmonary vasoconstriction and vascular
remodeling, hallmarks of PAH. These vasoactive compounds may result in a feedback loop to the nervous system. Various pharmacological (α/β blockers,
ACE inhibitors, AT1R inhibitors), surgical (pulmonary artery denervation (PADN), renal artery denervation) and experimental (Superior cervical and stellate
ganglion block (SGB) approaches for modulating autonomic nervous system and RAAS are also shown boxed in red
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cardiac output and may compensate for that by upregula-
tion of neurohormonal systems such as SNS and renin-
angiotensin-aldosterone system (RAAS) [12] (Fig. 1). In-
flammatory and RAAS molecules are specifically upregu-
lated in PAH and are implicated in the development of the
disease through their effects on the brain [13].
There is an increasing body of evidence linking auto-
nomic nervous system involvement in the pathogenesis
of PAH. Here we review the available literature on SNS
activation, heart rate variability, baroreflex sensitivity
and arrhythmias, and RAAS dysregulation in PAH. We
also summarize the therapeutic strategies for modulating
the autonomic nervous system and RAAS in PAH.
Sympathetic nervous system activation in PAH
Over the last 30 years, accumulating evidence has sup-
ported the involvement of the autonomic nervous
system in PAH, strengthening the hypothesis for the role
of SNS activation in PAH development. Microneurogra-
phy was used to compare the muscle sympathetic nerve
activity (MSNA) between patients with PAH and healthy
controls and showed increased sympathetic nerve traffic
in PAH patients [14]. MSNA was also directly correlated
with heart rate, presence of pericardial effusion, oxygen
saturation, New-York Heart Association class, 6-min
walk distance (6-MWD), and pulmonary arterial acceler-
ation time and was associated with clinical deterioration
[14, 15]. Administration of hyperoxia decreased MSNA
frequency and burst amplitude, suggesting that periph-
eral chemoreceptors contribute in part to increased
MSNA [14].
Increased SNS activity in PAH was also assessed by neu-
rohormonal activation, despite conflicting results between
studies. In a small clinical study comprising 32 patients
with PAH, plasma norepinephrine concentration was
strongly correlated to PVR and was associated with poor
estimated 5-year survival [16]. Some other studies have
shown an increase in plasma norepinephrine concentra-
tion in PAH patients compared to healthy controls, al-
though these norepinephrine levels did not exceed normal
values and were not correlated with any hemodynamic
parameter [17, 18]. To determine the involvement of cat-
echolamine pathway in PAH, many groups have directed
their research towards catecholamine receptors.
Bristow and colleagues [19] were the first to describe
local changes in β-adrenergic receptors in the failing RV
myocardium of PAH patients. Since then, the impact of β-
adrenergic receptor signaling in PAH development has
been extensively studied using different α/β-adrenergic re-
ceptor agonists/antagonists. Ishikawa and colleagues [20]
showed that administration of arotinolol, a pure α/β-adren-
ergic receptor antagonist, prevents monocrotaline (MCT)-
induced PH development by keeping cardiopulmonary
pressures below pathological threshold and decreasing RV/
body weight ratio in treated rats. Treatment with the non-
selective adrenergic receptor antagonist carvedilol was also
reported to reverse established RV failure in two different
rat models of PH (Sugen/hypoxia and MCT-induced PH)
and improved survival in MCT rats [21, 22]. This improve-
ment in RV function was associated with reduced RV
hypertrophy, dilation, and fibrosis, as well as an improved
capillary density of the myocardium [21]. Interestingly, car-
vedilol also decreased pro-fibrotic signaling and extracellu-
lar matrix remodelling in right and left ventricles of treated
rats via transforming growth factor-β1, connective tissue
growth factor, SMAD2/3, p38, and metalloproteinases 2
and 3 pathways. Drake and colleagues [23] performed an
extensive microarray gene expression analysis on the RV of
Sugen/hypoxia PH rats either treated with carvedilol for
4 weeks or untreated. Within the top canonical pathways
revealed in this analysis, one was involved in cardiac hyper-
trophy by protein synthesis and included regulation of
eukaryotic initiation factor 4 and 5 and p70S6k signaling,
all of which were downregulated with carvedilol. Ceramide
signaling and glucocorticoid receptor signaling pathways,
considered injurious for the heart, were also two of the top
five canonical pathways and were downregulated in
carvedilol-treated rats. Other canonical pathways included
the peroxisome proliferator-activator receptor signaling,
peroxisome proliferator-activator receptor/retinoid X
receptor-activation, and nuclear respiratory factor 2-
mediated oxidative stress response. These pathways are in-
volved in metabolism, mitochondrial function, and oxida-
tive stress response and are critical for adequate heart
function. All these findings highlight the role of adrenergic
receptors in RV failure and suggest that the use of β-
blockers could be beneficial for PAH patients. In the clinical
settings, carvedilol showed encouraging results by improv-
ing RV ejection fraction in chronic heart failure [24] and
did not lead to any notable adverse event or deterioration
[25, 26] (Table 2). In a recent 6-month double-blind, ran-
domized, controlled trial, patients treated with carvedilol
had an improved heart rate recovery after exercising com-
pared to those who received placebo [26]. This is important
since heart rate recovery after exercise is not only a pre-
dictor of increased risk of death but also of clinical worsen-
ing in PAH. RV function was also assessed by an improved
glycolytic rate related to carvedilol treatment. [26] Clinical
trials are still ongoing to confirm the therapeutic benefit
and safety of carvedilol in PAH patients (ClinicalTrials.gov
Identifier: NCT02120339 and NCT02507011).
De Man and colleagues [27] investigated the use of
bisoprolol, a cardioselective β-adrenergic receptor
blocker, in the progession of RV failure in MCT-induced
PH model. They showed that RV failure progression was
significantly delayed in bisoprolol treated rats with an
improvement in RV contractility and filling, a partially
recovered cardiac output, and decreased RV interstitial
Vaillancourt et al. Respiratory Research  (2017) 18:201 Page 5 of 15
Table 2 Clinical trials on neurohormonal modulation in pulmonary hypertension
Study Treatment Study design Follow-
up
Subjects Patient
description
(n patient)
Changes in outcomes Related side
effects (n patient)
Pharmacological therapies
Grinnan and
colleagues [25]
Carvedilol Single-arm,
open-label, pilot
6 months 6 iPAH (3)
HPAH (1)
APAH (2)
↑RVEF
↑BNP level
Bradycardia (1)
Asymptomatic
hypotension (1)
Mild fatigue (1)
Farha and
colleagues [26]
Carvedilol Single-center,
double-blind,
randomized,
controlled trial
6 months 30 iPAH (9)
HPAH (12)
APAH (5)
PH due to lung disease
and/or hypoxemia (2)
Chronic
thromboembolic PH (2)
↓HR
↓ RVSP at 3 month
follow-up
↑ RV fractional area
change at 3 month
follow-up
↑RV glycolytic rate
↑β-adrenergic receptor
density
Fatigue (1)
Dyspnea (2)
Leg swelling (3)
Site infection/acute
bronchitis (2)
Chest pain (1)
Blurry vision (1)
Cholecystitis (1)
Bloating (1)
Nausea/vomiting (1)
Dizziness (1)
van Campen
and colleagues
[29]
Bisoprolol Prospective,
randomised,
placebo-controlled,
crossover
1 years 18 iPAH (18) ↓HR
↑PAWP
↓Cardiac index
↓6-MWD
Worsening of fluid
retention (1)
Hypotension (1)
Tiredness (1)
Feelings of
depression (1)
Bandyopadhyay
and colleagues
[31]
Atenolol
Bisoprolol
Carvedilol
Metaprolol
Nebivelol
Propranolol
Sotalol
Retrospective
cohort
5 years 568 iPAH (260)
APAH (308)
None reported Therapy
discontinued (60):
Hypotension (18)
Shortness of breath
(14)
Volume overlaod
(12)
Fatigue (7)
Bradycardia/
Syncope (4)
Intolerance (3)
Other (2)
Moretti and
colleagues
[32]
Atenolol
Bisoprolol
Metaprolol
Nadolol
Propranolol
Prospective
cohort
2 years 94 iPAH (14)
APAH (27)
Post pulmonary
embolism (13)
Out of proportion (8)
Mixed (5)
Unknown (27)
↑TAPSE
↓RV diameter
↓HR
↓Systolic blood
pressure
None reported
So and
colleagues [33]
Acebutolol
Atenolol
Bisoprolol
Metaprolol
Nadolol
Propranolol
Prospective
cohort
2 years 94 iPAH (53)
Drug/toxin-iduced PAH
(2)
APAH (39)
↑Cardiac index None reported
Thenappan
and colleagues
[34]
Atenolol
Carvedilol
Labetalol
Metaprolol
Nadolol
Propranolol
Retrospective
cohort study,
propensity
score analysis
5 years 564 iPAH (250)
HPAH (17)
Drug/Toxin-induced
(21)
APAH (273)
Other (3)
None reported None reported
Bozbas and
colleagues [
60]
Losartan
Nifedipine
Prospective,
randomized
2 months 63 PH due to left heart
disease (40)
PH due to lung disease
and/or hypoxemia (23)
↓mean PAP
↑RVEF
↑6-MWD
↓VE
↓VE/VCO2
↑PETCO2
↑CPET test duration
None reported
2 months 199 Primary PAH (126) ↑6-MWD
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fibrosis and myocardial inflammation. Bisoprolol restored
β-adrenergic receptor signaling assessed by increased
phosphorylation of its downstream targets, myosin binding
protein C and troponin I. In contrast, decreased phosphor-
ylation of these proteins in PAH cardiomyocytes leads to
an increase in sarcomere Ca2+ sensitivity, thus impairing
RV relaxation and contributing to RV stiffness [28]. How-
ever, these beneficial effects were not confirmed in an ex-
plorative study involving 18 PAH patients (Table 2) [29].
In this randomized, placebo-controlled, crossover study,
bisoprolol did not improve patients’ conditions. Despite a
trend to increase RV ejection fraction, patients had a sig-
nificant decrease in cardiac index and a near significant
drop in 6-MWD, demonstrating no real benefit of bisopro-
lol in PAH (Table 2).
Finally, Perros and colleagues [30] compared the effects
of nebivolol, a third generation β-adrenergic receptor
blocker, to the first generation β1-adrenergic receptor
blocker metoprolol in MCT-induced PH rats. Nebivolol is
a β1-adrenergic receptor antagonist and β2,3-adrenergic
receptor agonist and has vasodilator properties in addition
to its adrenergic-modulating characteristics. Daily adminis-
tration of nebivolol for one week in established PH im-
proved cardiopulmonary hemodynamics and partially
reversed RV hypertrophy and pulmonary vascular remodel-
ing with a greater effect than metropolol. In vitro nebivolol,
but not metropolol, significantly decreased human pul-
monary endothelial cell proliferation as well as the produc-
tion of pro-inflammatory cytokines such as interleukin-6
and monocyte chemoattractant protein-1, epidermal and
fibroblast growth factors, and the vasoconstrictor
endothelin-1. Furthermore, human smooth muscle cell
proliferation was decreased when cells were cultured in the
endothelial cell + nebivolol-conditioned media [30]. A clin-
ical trial is currently recruiting patients to assess the thera-
peutic potential and safety of nebivolol in clinical
Table 2 Clinical trials on neurohormonal modulation in pulmonary hypertension (Continued)
Study Treatment Study design Follow-
up
Subjects Patient
description
(n patient)
Changes in outcomes Related side
effects (n patient)
Maron and
colleagues [69]
Spironolactone
±Ambrisentan
Retrospective
analysis of
randomized,
placebo-controlled
trials ARIES-1 and 2
Nonprimary PAH (73) ↓BNP level
↓WHO class
Pulmonary
hypertension (21)
Edema or
prevention of
edema (11)
RV failure (7)
Electrolyte
imbalance (1)
Invasive strategies
Chen and
colleague [74]
PADN Prospective
cohort
3 months 21 iPAH (21) ↓mean PAP
↓PVR
↓RVSP
↓TPG
↓Pericardial effusion
↑PA compliance
↑6-MWD
↓WHO class
↓NT-proBNP level
↓Rehospitalization
Chest pain (10)
Chen and
colleagues [75]
PADN Prospective
cohort, single-arm
1 year 66 iPAH (20)
APAH (19)
PH due to left
heart disease (18)
Chronic
thromboembolic PH (9)
↓mean PAP
↓PVR
↓RVSP
↑Cardiac output
↓Right atrial diameter
↓RV diameter
↓pericardial effusion
↑6-MWD
↓NT-proBNP level
Chest pain (47)
Sinus bradycardia (1)
Intolerance
to dyspnea (3)
6-MWD 6-min walk distance, APAH associated pulmonary arterial hypertension, BNP brain natriuretic peptide, CPET cardiopulmonary exercise testing, HPAH herit-
able pulmonary arterial hypertension, HR heart rate, iPAH idiopathic pulmonary arterial hypertension, NT-proBNP N-terminal pro-brain natriuretic peptide, PA pul-
monary artery, PAH pulmonary arterial hypertension, PAP pulmonary arterial pressure, PAWP pulmonary artery wedge pressure, PETCO2 end-tidal carbon dioxide
tension, PH pulmonary hypertension, PVR pulmonary vascular resistance, RV right ventricle, RVEF right ventricular ejection fraction, RVSP right ventricular systolic
pressure, TAPSE tricuspid annular plane systolic excursion, TPG transpulmonary pressure gradient, VCO2 volume of carbon dioxide production, VE pulmonary venti-
lation, WHO class World Health Organization Class
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managment of the PAH patients (ClinicalTrials.gov Identi-
fier: NCT02053246).
Despite encouraging results of adrenoreceptor block-
ade in experimental PH, the use of β-blockers in clinical
PAH is still largely debated due to the poor beneficial re-
sults as well as safety concerns revealed in clinical trials
[31–36] (Table 2). Although β-blockers partially reverse
RV structural and molecular remodeling [23, 24] and
seem beneficial and well-tolerated at low or escalating
doses [25, 26, 29, 31–34], their negative inotropic and
chronotropic effects may actually impair RV function in
severe heart failure. Thus, the choice based on the speci-
ficity of the β-blocker used to target one or the other β-
receptor sub-type may be of importance. The divergent
results found in clinical studies may also be the conse-
quence of several limiting factors, such as study design,
cohort size, diversity in pulmonary hypertension etiology
within cohorts, and variability in pre-existing comorbidi-
ties and treatments taken by patients.
Heart rate variability and baroreflex sensitivity in
PAH
Heart failure is associated with abnormalities in autonomic
nervous system control, including decreased heart rate vari-
ability and blunted baroreflex sensitivity [37], which were
predictors of cardiovascular mortality among post-
myocardial infarction patients [38, 39]. Considering the evi-
dence of an altered autonomic control in PAH, these two
parameters were investigated in different PAH cohorts. In a
small cohort of 9 PAH patients, heart rate variability was
assessed by a time-domain method and was found to be
significantly decreased compared to the control group (n =
20) [40]. In a larger cohort, Wensel and colleagues [41]
used a frequency-domain method to show a reduction of
total power of heart rate variability in PAH patients (n =
42) compared to healthy subjects (n = 41) but without any
significant difference between low/high frequency power
ratio. Baroreflex sensitivity was also reduced in PAH pa-
tients, determined by the controlled breath method and the
α-index of low frequency. Both heart rate variability and
baroreflex sensitivity parameters were correlated with de-
creased peak oxygen uptake during exercise, demonstrating
the impact of cardiac autonomous modulation in exercise
capacity [41]. In a cohort of 47 children with severe PAH,
heart rate variability was correlated with 6-MWD and was
predictive of transplantation and/or mortality [42]. On bi-
variate analysis, standard deviation of mean values for the
beat-to-beat interval over 5 min predicted outcome inde-
pendently of functional status, syncope, RV function, and
haemodynamic parameters [42]. More recently, Yi and col-
leagues [43] also confirmed that time-domain heart rate
variability parameters, as well as frequency-domain indices,
were significantly decreased in PAH patients (n = 26) com-
pared to the controls (n = 51). Furthermore, heart rate
variability parameters correlated to mean pulmonary arter-
ial pressure (PAP) in patients [44, 45]. Further studies in
larger patient cohorts are needed to confirm if the heart
rate variability and baroreflex sensitivity changes seen in
PAH are indeed associated with a decrease in the vagal tone
and whether they carry prognostic significance.
Cardiac arrhythmias in PAH
In experimental PH, our group and others have described
spontaneous ventricular fibrillation events and have exten-
sively investigated their mechanisms [46–48]. Benoist and
colleagues [46] showed in isolated hearts that the mono-
phasic action potential duration at 25, 50 and 90% repolari-
zation was significantly prolonged in hearts from MCT-
induced PH rats compared to controls for both RV and LV.
Futhermore, RV monophasic action potential duration at
90% repolarization strongly correlated with cardiac hyper-
trophy. These changes in the action potential duration were
associated with decreased K+ and L-type Ca2+ channel ex-
pressions as well as an increase in T-type Ca2+ channels in
the RV of MCT rats [46]. In a subsequent study, the same
group monitored MCT rats using electrocardiograms and
showed an increased QT interval in RV failure from day 15
post-MCT injection consistent with the prolonged action
potential duration [47]. Alternans of bothT-wave amplitude
and QT interval were also observed in animals with heart
failure. In isolated hearts, alternans occurred in four out of
six failing hearts and were always discordant. Action poten-
tial duration alternans have been associated with dysfunc-
tional Ca2+ homeostasis, resulting in increased intracellular
Ca2+ concentration and contractile alternans. Ca2+ transient
alternans were confirmed in isolated myocytes from failing
RVs and were shown to be provoked by dysregulation of
sarcoplasmic Ca2+ uptake, load, and release. Consistent
with this, failing RVs of MCT rats showed a reduced SER-
CA2a activity, an increased sarcoplasmic reticulum Ca2+ re-
lease fraction, and an increased Ca2+ spark leak. [47].
In MCT rats, our group [48] showed that the onset of ven-
tricular fibrillation was preceded by early afterdepolarizations,
triggering an activity which caused a non-sustained ventricu-
lar tachycardia which then degenerated to ventricular fibrilla-
tion. PH-induced RV failure was associated with RV
epicardial and endocardial fibrosis, which is known to pro-
mote early afterdepolarizations by cardiomyocytes and cause
ventricular fibrillation. In addition to fibrosis, we proposed
that a selective downregulation of Kv1.5, KCNE2, and SER-
CA2a in failing RV may lead to reduction of RV myocyte re-
polarization reserve, which could also facilitate the formation
of early afterdepolarizations [48]. These episodes of ventricu-
lar fibrillation were detected between days 23 and 32 after
MCT injection, corresponding to a period of expected sud-
den death in these animals. We also showed a 10-day win-
dow between the drop of RV ejection fraction (from ~72% at
day 14 to ~38% at day 21) and the beginning of this sudden
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death period, suggesting that mortality during this critical
period may be caused by early afterdepolarizations-mediated
triggered activity in the RV [48].
In clinical PAH, cardiac arrhythmias are common in
patients and are associated with worsening prognosis.
Cardiac arrhythmias include supraventricular arrhyth-
mias (SVA), which are the most common with a re-
ported incidence between 11 and 30% [49–53], and
the ventricular arrhythmias, which were reported to
be relatively rare in PAH [40]. The most common
SVAs seen in PAH patients are atrial fibrillation, flut-
ter, and tachycardia [49, 51, 53]. In a 6-year retro-
spective single-center analysis including 231 PAH
patients, 31 SVA episodes were detected in 27 pa-
tients (cumulative incidence 11.7%, annual risk 2.8%
per patient) [49]. In most episodes (n = 26), onset of
supraventricular tachycardia resulted in clinical deteri-
oration and/or RV failure. Furthermore, mortality was
significantly higher in patients with persistent atrial
fibrillation compared with the patients in whom sinus
rhythm was restored. In a 5-year prospective study
including 239 patients, at least one episode of atrial
flutter or atrial fibrillation was detected in 20% of the
patients [50]. Compared to patients who did not de-
velop SVA, patients who developed atrial flutter and
fibrillation had significantly higher baseline values for
right atrial pressure, mean PAP, PVR, lower baseline
values for cardiac output, and mixed venous oxygen
saturation. Futhermore, the estimated 1, 2, 3, and
5 year survival rates after diagnosis of PH in patients
with permanent atrial fibrillation were 80, 66, 22, and
22%, respectively [50]. Presence of SVA in PAH pa-
tients is also associated with deterioration of the RV
function, assessed by an increase in B-type natriuretic
peptide, atrial and ventricular diameter, mean atrial
pressure, and PVR, as well as a reduction of the car-
diac index [51]. The estimated survival rate is lower
in patients who develope SVA, and is significantly
worse in patients with permanent SVA compared to
transient or without SVA [51, 52]. A good under-
standing of cardiac arrhythmias and other autonomic
nervous system dysregulations is important not only
because they are determinants of the outcome for the
patients, but they also determine the clinical manage-
ment of PAH in these patients [49, 53].
Renin-angiotensin-aldosterone-system
dysregulation in PAH
Chronic activation of the RAAS in PAH patients is well de-
scribed. As extensively reviewed by Maron and Leopold,
RAAS activation promotes pulmonary vasoconstriction, cell
proliferation, migration, extracellular matrix remodeling
and fibrosis resulting in pulmonary vascular remodeling in
experimental PH (Fig. 2) [54].
Fig. 2 Renin-angiontensin-aldosterone system (RAAS) activation in PAH. Renin cleaves angiotensinogen to angiotensin I, which is further processed by the
angiotensin-converting enzyme (ACE) to the biologically active peptide angiotensin II and binds to angiotensin receptors AT1 and AT2. Angiotensin I and II
may also undergoe further processing by ACE2 to yield angiotensin (1–7), which activates the Mas receptor. On the other hand, aldosterone activates the
mineralocorticoid receptors. Both AT1 and mineralocorticoid receptor activation lead to pathological signaling in PAH, and targeting these pathways using
receptor antagonists or ACE inhibitors improves PAH. On the other hand, AT2 and Mas signaling are protective, and promoting these signaling cascades
using AT2 agonists or ACE2 activators improves autonomic nervous system imbalance seen in PAH
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Renin, angiotensin I, and angiotensin II
In PAH patients, circulating renin activity as well as
plasma angiotensin I and II are significantly up-regulated
and associated with disease worsening, suggesting a role
for systemic RAAS activation in PAH progression [12, 55].
Futhermore, plasma renin and angiotensin II were
strongly associated with an increased risk of death or lung
transplant, making them potentially reliable biomarkers
for clinical prognosis [12]. To determine whether local
RAAS activation was also involved in PAH, de Man et al.
[12] investigated angiotensin II signaling pathway in hu-
man PAH lung tissues. They found a two-fold increase of
angiotensin II receptor AT1, but not AT2, in the pulmon-
ary vasculature of PAH patients along with an increase in
activity of its downstream targets Src and ERK. This is an
important finding given that AT1 signaling is involved in
vasoconstriction, oxidative stress, inflammation, and pro-
liferation, while AT2 signaling leads to vasodilation and is
vasculoprotective (Fig. 2) [54]. Exposing pulmonary endo-
thelial cells to angiotensin I revealed a significatly in-
creased angiotensin II production by cells isolated from
PAH patients compared to control, which was abolished
with the angiotensin-converting enzyme (ACE) inhibitor
enalapril [12]. This high angiotensin II production by
endothelial cells induces smooth muscle cell proliferation,
resulting in pulmonary vascular medial hypertrophy and
obliteration. In vivo, pharmacological AT1 receptor antag-
onism using losartan significantly delayed disease progres-
sion in MCT-induced PH rats by reducing RV afterload,
restoring ventricular–arterial coupling, and improving RV
diastolic function. Furthermore, losartan significantly re-
duced pulmonary vascular remodeling in treated-rats but
without any change in RV hypertrophy [12]. However,
these results are inconsistent with previous studies in
MCT rats using the same AT1 antagonist, in which re-
searchers did not find any prophylactic effect of losartan
against the development of PAH [56, 57]. Two independ-
ent groups also tested losartan in a pressure-overload right
heart failure model. Borgdorff and colleagues [58] treated
pulmonary artery banded (PAB)-rats with combined losar-
tan + eplerenone treatment until RV failure criteria were
met or for a maximum of 11 weeks. Combined losartan +
eplerenone treatment did not prevent adverse RV remod-
eling or clinical RV failure. Interestingly, treated PAB rats
did have a significant decrease in LV peak and aortic pres-
sures, highlighting inherent differences between right and
left ventricles and their significance in research for therap-
ies in the context of PAH [58]. PAB model was also used
to compare the preventive effect of losartan and bisoprolol
on development of RV hypertrophy and dysfunction [59].
After 6 weeks of treatment with either losartan or bisopro-
lol, rats did not show any signs of improvement in RV
hypertrophy, dysfunction, fibrosis or capillary density. Fur-
thermore, neither losartan nor bisoprolol reversed gene
expression levels of cardiac hypertrophy and dysfunction
biomarkers.This study is additional evidence of how the
RV differs substantially from the LV when responding to
inhibition of the increased neurohormonal activation oc-
curring in heart failure.
In the clinical setting, 33 PH patients from different
etiologies were followed after 8 week- treatment of losar-
tan (Table 2) [60]. A modest but significant decrease in
mean PAP and increase in RV ejection fraction were ob-
served in subjects taking losartan compared to their
baseline. They also found an improvement in 6-MWD
and in several cardiopulmonary exercise testing parame-
ters. However, the duration of treatment was relatively
brief, and the study was lacking a control group. Fur-
thermore, since the cohort was comprised of subjects
from different PH classification groups, further studies
are needed to assess the real potential of losartan in
PAH patients.
ACE2/Angiotensin-(1–7)/Mas axis
Another method to counter the vasoconstrictive and pro-
liferative ACE/angiotensin II/AT1 receptor axis in PAH
was demonstrated by activating the vasoprotective ACE2/
Angiotensin-(1–7)/Mas axis of the RAAS. Ferreira and
colleagues [61] administered the compound XNT, a syn-
thetic activator of ACE2, in MCT-induced PH rats during
the 28 days of the protocol. XNT significantly decreased
RV pressure and hypertrophy in treated rats. This improv-
ment was abolished when XNT was co-administrered
with A779, a Mas antagonist, supporting the hypothesis
that beneficial effects of ACE2 activation would be medi-
ated by an increase in Ang-(1–7) levels to shift the balance
from the ACE/angiotensin II/AT1 receptor axis toward
the ACE2/Angiotensin-(1–7)/Mas axis of the RAAS.
MCT treatment alone caused significant increases in renin
and angiotensinogen mRNA as well as in the AT1 recep-
tor and ACE mRNA levels, all of which were reversed
with XNT treatment. ACE2 activation also significantly at-
tenuated the mRNA levels of the inflammatory mediators
tumor necrosis factor-α, interleukin-1, interleukin-6,
monocyte chemoattractant protein-1, as well as nuclear
factor-kappa B p50 and p65 [61]. Similar results were
found when MCT rats were treated with compound C21,
an AT2 receptor agonist, suggesting an endogenous pro-
tective role of AT2 receptors in PH [62]. Interestingly, ei-
ther AT2 receptor or Mas blockade prevented the
protective effect of the C21, suggesting a connection be-
tween both receptors. The same group showed that daily
oral administration of 500 mg of bioencapsulated ACE2
or angiotensin-(1–7) prevents and rescues MCT-induced
PH, with a greater effect when both therapies were com-
bined [63]. ACE2 and angiotensin-(1–7) improved RV
function, and decreased pulmonary vascular wall thickness
and inflammatory markers as well as autophagy assessed
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by the reduction of LC3B-II protein level. Li and col-
leagues [64] demonstrated the prevention of PH using the
pharmacological compound resorcinolnaphthalein, an
ACE2 activator, in a severe PH model. Briefly, they
injected a single dose of MCT (40 mg/kg) 1 week after
performing pneumonectomy in rats. At the time of MCT
injection, they implanted osmotic minipumps containing
either resorcinolnaphthalein or the vehicle for 21 days of
infusion. ACE2 activation decreased mean PAP and subse-
quent RV hypertrophy without any effect on systemic
pressure. This change in mean PAP was at least in part
due to a partial restoration of acetylcholine-induced pul-
monary vasorelaxation. Resorcinolnaphthalein also de-
creased the neointimal formation in small pulmonary
arteries, from 95% in MCT + pneumonectomy group to
29% in treated rats. In accordance with the findings of Fer-
reira and colleagues [61], beneficial effects of ACE2 activa-
tion in PAH seem to be at least partly mediated through
angiotensin-(1–7)/Mas axis, since improvements of mean
PAP, RV hypertrophy, pulmonary vasorelaxation, and neo-
intimal formation were all abolished by the Mas antagon-
ist A779 [64]. Finally, the role of ACE2/angiotensin (1–7)/
mas axis in autonomic nervous system modulation was
demonstrated using diminazene aceturate, a putative
angiotensin 1–7 converting enzyme activator [65]. Dimin-
azene treatment resulted in significant improvement in
power spectrum parameters, such as normalized high and
low frequency components in treated rats compared to
MCT alone, thus reversing the imbalance in the auto-
nomic nervous system modulation seen in PH. Clinical
trials are now in progress to assess mechanism, safety, and
efficacy of ACE-2 treatment for PAH patients (Clinical-
Trials.gov Identifier: NCT01884051 and NCT03177603).
Aldosterone
Another key player of RAAS is the steroid hormone al-
dosterone. Maron and colleagues [66] found an increase
of aldosterone levels in plasma and lung tissues of
MCT- and Sugen/hypoxia-induced PH animals. Elevated
aldosterone levels were mediated by endothelin-1 via
peroxisome proliferator-activated receptor gamma
coactivator-1α/steroidogenesis factor-1, and increased
oxidative stress in pulmonary artery endothelial cells,
leading to an inhibition of nitric oxide production. Both
in preventive and rescue protocols, spironolactone, a
mineralocorticoid receptor antagonist, improved RV
hypertrophy, PAP, PVR, and pulmonary artery remodel-
ing along with decreased reactive oxygen species gener-
ation and restoration of nitric oxide production [66].
The therapeutic effect of spironolactone was further
confirmed in a chronic hypoxia-induced PH mouse
model [67]. Furthermore, the latest study demonstrated
that mineralocorticoid receptor, once activated by aldos-
terone, induces transcriptional activity and proliferation
in pulmonary arterial smooth muscle cells, which was
prevented by spironolactone [67].
In a clinical study, Maron and colleagues [68] confirmed
hyperaldosteronism in a small cohort of PAH patients..
Among controls (n = 5) and treatment-naïve PAH patients
(n = 6), aldosterone levels also positively correlated with
PVR and transpulmonary gradient and inversely corre-
lated with cardiac output. Maron and colleagues [69] also
analyzed the data from patients in whom spironolactone
use was reported during ARIES-1 and -2 studies, which
were randomized, double-blind, placebo-controlled trials
assessing the effect of the endothelin receptor antagonist
ambrisentan for 12 weeks on clinical outcomes in PAH
(Table 2). Compared to patients treated with ambrisentan
alone (n = 57), patients in whom spironolactone therapy
was reported during the trial (n = 10) had a trend toward
further improvement in 6-MWD, a 1.7 fold increase in
B-type natriuretic peptide plasma levels, as well as im-
provement in World Health Organization functional clas-
sification. However, a recent and larger study showed no
association between B-type natriuretic peptide levels,
6-MWD, Borg dyspnea score, RV systolic pressure, cardiac
output, or cardiac index [70]. Aldosterone levels were also
not associated with mortality. This discrepancy highlights
the need for further investigations on larger cohorts to de-
fine the usefulness of aldosterone antagonism in PAH.
Clinical trials are actually ongoing to define the effect,
safety and tolerability of the use of aldosterone antagonists
in PAH (ClinicalTrials.gov Identifier: NCT01468571,
NCT01712620, NCT02253394).
Invasive strategies for modulating the autonomic
nervous system in PAH
Sympathetic ganglion block for the attenuation of
experimental PH
The activation of the SNS in PAH is well recognized, and,
as seen previously, different methodologies have been con-
sidered to decrease this activation and improve PAH. Na
and colleagues [71] investigated the therapeutic potential
of a sympathetic ganglion block (SGB) in experimental
PH (Fig. 1). Briefly, two weeks after MCT injection in rats,
they administered daily injections of either saline or ropi-
vacaine, a local anesthetic, into the left superior cervical
ganglion for 14 days. Compared to MCT rats treated with
saline, SGB significantly decreased RV pressures, RV
hypertrophy, and pulmonary arterial wall thickness. This
improvement was associated with a switch in endothelial
nitric oxide synthase and arginase activity in rats injected
with ropivacaine compared to those injected with saline,
resulting in an increase in lung cGMP and plasma nitrite
levels [71]. Finally, SGB decreased pulmonary oxidative
stress, assessed by a restoration of superoxide dismutase
activity and decreased malondialdehyde and nitrotyrosine
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levels in the lung tissues. These findings support SGB as a
potential novel therapeutic approach to treat PAH.
Pulmonary artery denervation for the treatment of PAH
Baroreceptors and sympathetic nerve fibers are localized
in or near the bifurcation area of the main pulmonary ar-
tery. Chen and colleagues [72] first tested pulmonary ar-
tery denervation (PADN) in baloon-occlusion-induced
PAH by occluding the left pulmonary interlobar artery in
10 Mongolian dogs. Five minutes after the occlusion, the
mean absolute hemodynamic changes reached their peak
with mean PAP Δ16.6 mmHg, RVSP Δ14.1 mmHg, and
PVR Δ1.144 dynes/s/cm5 compared to baseline. These
changes at five minutes were completely abolished with
the PADN treatment compared to baseline. Recently, the
nerve distribution around the pulmonary artery has been
investigated in a swine model to determine the effect of
radiofrequency PADN on acute PH induced by vasocon-
striction using thromboxane A2 agonist [73]. Mean PAP
was significantly decreased following thromboxane A2
agonist injection in swine treated with PADN (n = 4) com-
pared to the sham group (n = 4). This change correlated
with the number of histological denervation lesions in
pulmonary arteries. Furthermore, they demonstrated that
the depth of histological changes induced by radiofre-
quency energy delivery varied with anatomic location and
wall thickness, indicating that the location is critical to
successful PADN.
Chen and colleagues [74] tested for the first time the
safety and efficacy of PADN intervention in patients with
PAH (PADN-1 study). At 3 months follow-up, patients
who underwent PADN procedure (n = 13) showed signifi-
cant reduction of mean PAP and PVR and significant im-
provement of 6-MWD, World Health Organization class,
and N-terminal brain natriuretic peptide level compared
to control group (n = 8). A few years later, a phase II of
this study was performed in a cohort of 66 patients with
mixed PH ethiologies who all underwent PADN treatment
[75]. Compared to baseline, the 6 months follow-up con-
firmed an improvement of parameters cited above. None
of the parameters changed between the 6 months and
1 year follow-up, confirming the maintenance of benefical
effects (Table 2). These clinical studies are the demonstra-
tion of a promising new strategy for treatment of PAH.
However, these results should be interpreted carefully
since either there was no control group, or whenever there
was one, that group did not undergo the catheter insertion
(sham) procedure. Furthermore, PADN procedure should
be tested in combination with current pharmacological
therapies used in PAH. In summary, further clinical trials
testing PADN in addition to current therapies, including a
control (sham) group, are needed to assess the effective-
ness and safety of PADN strategy in the treatment of
PAH. Clinical trials are ongoing to assess the efficacy of
this technique in PAH (ClinicalTrials.gov Identifier:
NCT02516722, NCT02220335 and NCT02525926).
Catheter-based renal denervation as a treatment of PAH
Catheter based renal denervation is an intervention that
reduces activation of the SNS and the RAAS (Fig. 1) by
destroying sympathetic nerve fibers of the renal periar-
terial nerve plexus via small bursts of radiofrequency en-
ergy along the lengh of the nerve. Qingyan and
colleagues [76] reported the first preclinical results of
this strategy in a proof-of-concept study that evaluated
the efficacy of catheter renal denervation as a treatment
for PAH in a canine MCT experimental model. Renal
denervation improved cardiopulmonary hemodynamics,
attenuated pulmonary vascular remodeling, and de-
creased myocardial fibrosis in experimental PH. At the
molecular level, renal denervation reduced angiotensin
II type-1, but not type 2, receptor expression in the pul-
monary arterial tissue [76]. However, these beneficial ef-
fects should be analyzed cautiously, since this study lack
of control-stimulation (sham) group. This is particularly
important since a large, prospective, single-blind, ran-
domized, sham-controlled trial reported a significant de-
crease of the systolic blood pressure in the sham group
(n = 171) as well as in systemic hypertensive patients
(n = 364) [77]. Very recently, a group responded to this
important issue by performing renal denervation 24 h
and 2 weeks after MCT injection in rats, with control
groups undergoing a sham renal denervation surgery
[78]. After a 35 days follow-up, they confirmed the bene-
ficial effects of this procedure on the lung and cardiac
histopathology. Interestingly, the sooner the surgery was
performed during the development of the disease, the
better were the results. These exciting results support a
potential benefit of catheter-based renal denervation for
the treatment of PAH patients.
Conclusions
Although PAH is generally associated with increased sym-
pathetic nervous system activation, the precise role of
autonomic nervous system involvement in the pathogen-
esis of PAH is still not fully understood. Pharmacologic
adrenergic blockade, reduction of neurohormonal activa-
tion, and novel direct methods to attenuate sympathetic
nervous system activation such as renal denervation and
pulmonary artery denervation may be beneficial in PAH.
Further studies are needed to determine the extent of in-
volvement of the autonomic nervous system in PAH and
to assess the effectiveness and safety of targeting the auto-
nomic nervous system and RAAS for the treatment of
PAH patients.
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